Catalyst Funds Management Pty LTD Cyclo Therapeutics, Inc. Transaction History

Catalyst Funds Management Pty LTD

  • $662 Billion
  • Q3 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Dec 04, 2024
BUY
$1.39 - $1.9 $93 - $127
67 New
67 $93,000

Others Institutions Holding CYTH

# of Institutions
2
Shares Held
749K
Call Options Held
0
Put Options Held
0
View Full List

About Cyclo Therapeutics, Inc.

CYTH Quotes by TradingView
  • Ticker CYTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 8,439,440
  • Market Cap $6.08M
  • Description
  • Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...
More about CYTH
Track This Portfolio

Track Catalyst Funds Management Pty LTD Portfolio

Follow Catalyst Funds Management Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Funds Management Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Funds Management Pty LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email